See more : Investcorp India Acquisition Corp (IVCAU) Income Statement Analysis – Financial Results
Complete financial analysis of Freeline Therapeutics Holdings plc (FRLN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Freeline Therapeutics Holdings plc, a leading company in the Biotechnology industry within the Healthcare sector.
- ZhongWang Fabric Co., Ltd. (605003.SS) Income Statement Analysis – Financial Results
- Gold Standard Ventures Corp (GSV.TO) Income Statement Analysis – Financial Results
- Sema4 Holdings Corp. (SMFR) Income Statement Analysis – Financial Results
- Park Aerospace Corp. (PKE) Income Statement Analysis – Financial Results
- Bangchak Corporation Public Company Limited (BCP-R.BK) Income Statement Analysis – Financial Results
Freeline Therapeutics Holdings plc (FRLN)
About Freeline Therapeutics Holdings plc
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.74M | 2.39M | 1.93M | 1.55M | 0.00 |
| Gross Profit | -1.74M | -2.39M | -1.93M | -1.55M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 66.20M | 95.43M | 76.15M | 47.04M | 34.19M |
| General & Administrative | 30.66M | 44.57M | 26.30M | 16.60M | 6.79M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.66M | 44.57M | 26.30M | 16.60M | 6.79M |
| Other Expenses | -1.57M | -2.09M | -15.27M | -10.60M | -390.00K |
| Operating Expenses | 95.29M | 137.91M | 87.18M | 53.05M | 32.72M |
| Cost & Expenses | 95.29M | 137.91M | 87.18M | 53.05M | 32.72M |
| Interest Income | 904.00K | 403.95K | 275.00K | 74.31K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 151.00K |
| Depreciation & Amortization | 1.27M | 9.24M | 17.18M | 12.14M | 970.00K |
| EBITDA | -97.17M | -133.14M | -85.27M | -51.51M | -32.14M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -98.45M | -142.38M | -102.45M | -63.64M | -40.98M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 9.84M | 2.33M | 6.26M | 9.88M | -470.80K |
| Income Before Tax | -88.60M | -140.05M | -96.19M | -53.77M | -33.26M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 368.00K | 342.00K | 129.00K | 141.00K | 27.00K |
| Net Income | -88.97M | -140.39M | -96.32M | -53.91M | -33.28M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -22.52 | -58.98 | -102.09 | -127.39 | -78.65 |
| EPS Diluted | -22.52 | -58.98 | -102.09 | -127.39 | -78.65 |
| Weighted Avg Shares Out | 3.95M | 2.38M | 943.52K | 423.19K | 423.19K |
| Weighted Avg Shares Out (Dil) | 3.95M | 2.38M | 943.52K | 423.19K | 423.19K |
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Freeline Posts Cases Of Lower FIX Expression, Higher Liver Enzymes From Hemophilia Candidate
Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress
Freeline To Present at the 25th Annual Meeting of the American Society of Gene and Cell Therapy
Freeline to Participate in Upcoming Investor Conferences
Freeline to Present on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposium™
Hot Penny Stocks to Watch Right Now That Are Moving in Premarket
Freeline Therapeutics Touts Encouraging Data From Fabry Disease Program
Freeline Therapeutics to Present FLT180a Data at the 2021 ASH Annual Meeting
Freeline Provides Executive Leadership Team Update; Company to Provide Corporate Update and Second Quarter 2021 Financial Results on Monday, August 16
Source: https://incomestatements.info
Category: Stock Reports